Skip to main content

Table 3 Characteristics of patients with diabetes according to concomitant events

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

  3. Diabetes w/o event 4. Diabetes with event
NHIS NHIS + Eze HIS HIS + Eze p value* NHIS NHIS + Eze HIS HIS + Eze p value*
Nr. patients n (%) 5661 (85) 447 (7) 532 (8) 33 (1)   2057 (54) 325 (9) 1289 (34) 115 (3)  
Adherent n (%) 4777 (84) 404 (90) 461 (87) 33 (100) < 0.001 1677 (82) 294 (91) 1085 (84) 106 (92) < 0.001
Total-chol (mg/dl)a 154.2 (34) 153.7 (37) 149.8 (37) 155.3 (48) N.S 138.8 (37) 136.9 (34) 130.5 (35) 136.6 (44) < 0.001
LDL-chol (mg/dl)a 81.7 (27) 79.6 (30) 79.2 (29) 87.5 (39) N.S 73.1 (28) 68.8 (27) 67.6 (27) 72.1 (36) < 0.001
HDL-chol (mg/dl)a 49.5 (15) 48.7 (14) 46.4 (14) 43 (9) < 0.001 42.6 (14) 43.7 (14) 41.1 (13) 41.5 (12) < 0.01
Triglycerides (mg/dl)a 108.9 (70) 122.5 (79) 114.3 (74) 109.2 (65) < 0.001 100.7 (68) 106.6 (71) 97.6 (71) 96 (61) N.S
NON-HDL-chol (mg/dl)a 104.7 (32) 105 (35) 103.4 (34) 112.3 (48) N.S 96.2 (34) 93.2 (31) 89.4 (33) 95.1 (43) < 0.001
GFR (ml/min/1.73 m2)a 94.7 (33) 92.5 (31) 93.8 (32) 98.7 (29) N.S 75.2 (37) 71.8 (37) 82 (36) 86.5 (40) < 0.001
HbA1c (mmol/mol)a 55.7 (13) 56.4 (13) 55.8 (13) 56 (15) N.S 55.1 (14) 54.4 (14) 56.2 (15) 56.9 (14) N.S
CHD       920 (45) 175 (54) 619 (48) 72 (63) < 0.001
Cerebrovascular disease       790 (38) 86 (27) 531 (41) 28 (24) < 0.001
PAD       8 (0) N.I N.I 0 (0) N.S
ACEi/ARB 3986 (70) 320 (72) 395 (74) 26 (79) N.S 1502 (73) 243 (75) 1000 (78) 91 (79) < 0.05
Beta blockers 1588 (28) 152 (34) 213 (40) 16 (49) < 0.001 1116 (54) 221 (68) 816 (63) 91 (79) < 0.001
CCB 1669 (30) 127 (28) 147 (28) 7 (21) N.S 742 (36) 119 (37) 491 (38) 43 (37) N.S
Fibrates 64 (1) 12 (3) 14 (3) 0 (0) < 0.01 22 (1) 5 (2) 15 (1) N.I N.S
Insulin 1366 (24) 136 (30) 154 (29) 9 (27) < 0.01 823 (40) 144 (44) 498 (39) 49 (43) N.S
Metformin 3724 (66) 258 (58) 333 (63) 25 (76) < 0.01 906 (44) 132 (41) 643 (50) 59 (51)  = 0.001
Sulfonylureas 1131 (20) 88 (20) 100 (19) N.I N.S 290 (14) 39 (12) 174 (14) 11 (10) N.S
DPP-4 300 (5) 36 (8) 25 (5) N.I N.S 171 (8) 29 (9) 89 (7) 7 (6) N.S
GLP-1 160 (3) 17 (4) 17 (3) N.I N.S 29 (1) 8 (3) 26 (2) 5 (4) N.S
SLGT2 69 (1) 12 (3) 11 (2) 0 (0) < 0.05 24 (1) 6 (2) 17 (1) 6 (5) < 0.01
  1. Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. CHD coronary heart disease, PAD peripheral artery disease, ACEi angiotensin converting-enzyme inhibitors, ARBs angiotensin II receptor blocker, CCB calcium channel blockers
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index